| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Intellia Therapeutics, Inc. (NTLA) has 14 insiders with recent SEC Form 4 filings, including 1 buy and 11 sells. NTLA is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 1.01M | $14.28M | - | |
| Dir | 207.5K | $2.92M | - | |
| Dir | 134.7K | $1.90M | - | |
| VP | 121.2K | $1.71M | - | |
| VP | 101.5K | $1.43M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | Leonard John M83 | President And CEO | Sell | 34,146 | $9.21 | $314,484.66 | -3.3% | +41.9% | - | |
| Jan 5, 2026 | Schultes Birgit C | EVP, Chief Scientific Officer | Sell | 8,508 | $9.21 | $78,358.68 | -7.9% | +41.9% | - | |
| Jan 5, 2026 | Basta James72 | EVP, General Counsel | Sell | 10,397 | $9.21 | $95,756.37 | -9.3% | +41.9% | - | |
| Jan 5, 2026 | Lebwohl David87 | EVP, Chief Medical Officer | Sell | 11,903 | $9.21 | $109,626.63 | -8.9% | +41.9% | - | |
| Jan 5, 2026 | Clark Eliana78 | EVP, Chief Technical Officer | Sell | 9,515 | $9.21 | $87,633.15 | -9.8% | +41.9% | - | |
| Jan 5, 2026 | Dulac Edward J III81 | EVP, Chief Financial Officer | Sell | 6,379 | $9.21 | $58,750.59 | -6.0% | +41.9% | - | |
| Jan 5, 2026 | Dube Michael P53 | VP, Chief Accounting Officer | Sell | 2,989 | $9.21 | $27,528.69 | -5.4% | +41.9% | - | |
| Jan 5, 2026 | Cohen Fred E | Director | Buy | 150,000 | $9.35 | $1,402,500.00 | +261.1% | +41.9% | - | |
| Dec 11, 2025 | Leonard John M83 | President And CEO | Sale+OE | 88,146 | $9.49 | $836,384.40 | -2.7% | +36.2% | - | |
| Oct 1, 2025 | Schultes Birgit C | EVP, Chief Scientific Officer | Sell | 31 | $17.38 | $538.78 | - | -51.7% | - |